Featured Research

from universities, journals, and other organizations

Gene Therapy May Protect Normal Tissues During Radiation Retreatment For Lung Cancer

Date:
October 17, 2005
Source:
University of Pittsburgh Medical Center
Summary:
According to a University of Pittsburgh study presented at the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology, Oct. 16 to 20, gene therapy could be used as an agent to protect normal tissues from damage during a second administration of radiation therapy for non-small cell lung cancer. Administration of manganese superoxide dismutase plasmid liposome (MnSOD-PL) gene therapy prevented the damaging radiation effects in mice, even when the radiation was re-administered after six months.

DENVER, Oct. 16 -- Gene therapy could be used as an agent to protectnormal tissues, including the esophagus and lung, from damage during asecond administration of radiation therapy for non-small cell lungcancer, according to an animal study presented today by University ofPittsburgh researchers at the 47th Annual Meeting of the AmericanSociety for Therapeutic Radiology and Oncology (ASTRO) in Denver.

"A major challenge in treating lung tumors with radiation is thetoxicity of radiation to healthy tissue," said Joel S. Greenberger,M.D., professor, University of Pittsburgh School of Medicine. "This canresult in major quality-of-life issues for lung cancer patientsreceiving radiation therapy for their diseases. In previous studies, wedemonstrated that gene therapy may protect healthy tissues from damageprior to an initial course of radiation therapy. In this study, wefound that gene therapy also can protect the same healthy tissue duringretreatment with radiation." Dr. Greenberger explained that a relatedstudy shows the effectiveness of aerosol delivery of this therapy by aninhalation nebulizer making it clinically feasible.

In the study, animal models were used to test the protective effects ofmanganese superoxide dismutase plasmid liposome (MnSOD-PL) gene therapyduring exposure to radiation. One group of mice received anintratracheal injection of MnSOD-PL 24 hours before a course of 14 Gyirradiation, while a second group received 14 Gy irradiation alone. Themice were observed for six months for any toxic pulmonary effects andthen subdivided into two more groups. One of these groups was exposedto a second lung irradiation of 10 Gy without MnSOD-PL and the otherreceived an injection of MnSOD-PL 24 hours prior to radiation exposure.

The researchers found that in mice that received the initial 14Gy dose there was 50 percent survival at 180 days (due to lungtoxicity) compared to 87.5 percent survival during the same length oftime for mice that were injected with MnSOD-PL prior to irradiation.Mice that received MnSOD-PL before both the 14 Gy dose as well as thesubsequent 10 Gy dose had the best survival rate overall. Mice treatedwith MnSOD-PL before the first dose of radiation had a survival rate of31.6 percent, while mice receiving the treatment before both courses ofradiation had a survival rate of 47.6 percent.

"Administration of this type of gene therapy appeared to prevent thedamaging effects of radiation, even when the radiation wasre-administered after six months," said Dr. Greenberger. "Futurestudies will tell us whether this therapy can improve the quality oflife for lung cancer patients and help us more effectively treat lungcancer without the damaging side effects."

Lung cancer is the leading cause of cancer-related death in men andwomen. In 2005, more than 170,000 new cases of lung cancer will bediagnosed. Side effects from radiation therapy for lung cancer caninclude fatigue, skin changes, swelling of the esophagus, hair loss inthe treated area, dry cough caused by swelling of the lung tissue andsore throat.

###

The study's co-authors include Lauren Hricisak and Michael W. Epperly,Ph.D., both with the department of radiation oncology at the Universityof Pittsburgh. The study was one of several funded by a SpecializedProgram in Research Excellence in Lung Cancer awarded to the Universityof Pittsburgh Cancer Institute by the National Cancer Institute in 2001.


Story Source:

The above story is based on materials provided by University of Pittsburgh Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

University of Pittsburgh Medical Center. "Gene Therapy May Protect Normal Tissues During Radiation Retreatment For Lung Cancer." ScienceDaily. ScienceDaily, 17 October 2005. <www.sciencedaily.com/releases/2005/10/051017071925.htm>.
University of Pittsburgh Medical Center. (2005, October 17). Gene Therapy May Protect Normal Tissues During Radiation Retreatment For Lung Cancer. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2005/10/051017071925.htm
University of Pittsburgh Medical Center. "Gene Therapy May Protect Normal Tissues During Radiation Retreatment For Lung Cancer." ScienceDaily. www.sciencedaily.com/releases/2005/10/051017071925.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins